Kostka, SL; Hurst, J; Demircik, F et al.
Anti-phospholipid antibodies opsonise L. major parasites to promote dendriticcell (DC) phagocytosis and induction of protective immunityEXPERIMENTAL DERMATOLOGY. Bd. 18. H. 3. 2009 S. 303-303
Waisman, A; Yogev, N
B7-H1 and CD8(+) Treg: The enigmatic role of B7-H1 in peripheral toleranceEUROPEAN JOURNAL OF IMMUNOLOGY. Bd. 39. H. 6. 2009 S. 1448-1451
Kukolj, G; Benhamou, Y; Manns, MP et al.
BI 201335, A POTENT HCV NS3 PROTEASE INHIBITOR, IN TREATMENT-NAIVE AND -EXPERIENCED CHRONIC HCV GENOTYPE-1 INFECTION: GENOTYPIC AND PHENOTYPIC ANALYSIS OF THE NS3 PROTEASE DOMAINJOURNAL OF HEPATOLOGY. Bd. 50. 2009 S. S347-S347
Zeller, N; Raasch, J; van Loo, G et al.
Brain-specific I kappa B kinase 2 is crucial for demyelination of the CNS but dispensable for myelin formation and repair.ACTA NEUROPATHOLOGICA. Bd. 118. H. 3. 2009 S. 465-465
Moehler, M; Sprinzl, MF; Abdelfattah, M et al.
Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patientsWorld J Gastroenterol. Bd. 15. H. 4. 2009 S. 449-56
Kuhlmann, CRW; Closhen, D; Huppert, J et al.
Cellular mechanisms of interleukin-17 induced blood-brain-barrier disruptionNAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY. Bd. 379. 2009 S. 49-49
Lorenzen, S; Schuster, T; Porschen, R et al.
Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische OnkologieAnn Oncol. Bd. 20. H. 10. 2009 S. 1667
Moehler, M; Trarbach, T; Seufferlein, T et al.
CETUXIMAB WITH IRINOTECAN/FOLINIC ACID/5-FU AS FIRST-LINE TREATMENT IN ADVANCED GASTRIC CANCER: A NON-RANDOMISED MULTI-CENTER AID PHASE II STUDYANNALS OF ONCOLOGY. Bd. 20. 2009 S. 25-25
Kanzler, S; Trarbach, T; Seufferlein, T et al.
Cetuximab with irinotecan/folinic acid/5-FU as first-line treatment in advanced gastric cancer: A nonrandomized multicenter AIO phase II studyJOURNAL OF CLINICAL ONCOLOGY. Bd. 27. H. 15. 2009 S. -
Mohler, M; Mueller, A; Trarbach, T et al.
Cetuximab with Irinotecan/Folinic Acid/5-FU as first-line treatment in advanced gastric cancer: a prospective multi-center phase II study and additional biomarkers of the Arbeitsgemeinschaft Internistische OnkologieEJC SUPPLEMENTS. Bd. 7. H. 2. 2009 S. 384-384